Page last updated: 2024-12-11

callystatin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

callystatin A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5471086
CHEMBL ID200899
CHEBI ID80782
SCHEMBL ID16072414
MeSH IDM0380045

Synonyms (20)

Synonym
2h-pyran-2-one,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraenyl)-5,6-dihydro-
189883-16-7
(2r)-2-[(1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-heptadeca-1,3,7,9-tetraenyl]-2,3-dihydropyran-6-one
2h-pyran-2-one, 6-[(1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraenyl]-5,6-dihydro-, (6r)-
callystatin a
nsc-708248
nsc708248
C16891
CHEMBL200899
chebi:80782 ,
(2r)-2-[(1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxoheptadeca-1,3,7,9-tetraenyl]-2,3-dihydropyran-6-one
2h-pyran-2-one, 6-((1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraenyl)-5,6-dihydro-, (6r)-
unii-zlk7n2r2d6
zlk7n2r2d6 ,
SCHEMBL16072414
Q5023018
DTXSID501029737
(6r)-6-((1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraen-1-yl)-5,6-dihydro-2h-pyran-2-one
2h-pyran-2-one, 6-(3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraenyl)-5,6-dihydro-, (6r-(6r*(1e,3z,5r*,7e,9e,11r*,13s*,14r*,15s*)))-
2h-pyran-2-one, 6-((1e,3z,5r,7e,9e,11r,13s,14r,15s)-3-ethyl-14-hydroxy-5,9,11,13,15-pentamethyl-12-oxo-1,3,7,9-heptadecatetraen-1-yl)-5,6-dihydro-, (6r)-

Research Excerpts

Overview

Callystatin A is a prominent member of a class of natural products which display promising growth inhibition of cancer cells in their biological profile.

ExcerptReferenceRelevance
"Callystatin A is a prominent member of a class of natural products which display promising growth inhibition of cancer cells in their biological profile. "( The total synthesis of (-)-callystatin A.
Burzlaff, A; Chary, KP; Kalesse, M; Kasper, C; Quitschalle, M; Scheper, T, 2003
)
2.06
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diterpenoidAny terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID258229Cytotoxicity against HCT116 human colon cancer cell line2006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Leptostatin: a synthetic hybrid of the cytotoxic polyketides callystatin A and leptomycin B.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's18 (85.71)29.6817
2010's3 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.30 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.76 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]